Year: 2021
Type: article
Abstract: BCMA/CD3ε-targeted bispecific antibody (BsAb) therapy represents a promising T-cell redirecting immunotherapy to treat relapsed and refractory multiple myeloma (MM). However, rational combination strategies will most likely be key to achieve a long-lasting immune response. In this issue, Meermeier and colleagues investigate BsAb therapy in a syngeneic MM model and elucidate that partnering with cyclophosphamide is associated with tempered activation, mitigated exhaustion of T-cells, and is superior to pomalidomide or bortezomib in enhancing durable anti-MM efficacy.
Source: Blood Cancer Discovery
Authors: Cedric Louvet, Omar Nadeem, Eric L. Smith
Institution: Dana-Farber Cancer Institute
Language: English
Subfield: Hematology
Field: Medicine
Domain: Health Sciences
Open Access status: bronze
Funders: Lymphoma Research Foundation, Multiple Myeloma Research Foundation, American Society of Hematology, Leukemia and Lymphoma Society, American Society of Clinical Oncology, Dana-Farber/Harvard Cancer Center, Society for Immunotherapy of Cancer, National Institutes of Health, National Cancer Institute
OpenAlex ID: W3171435506